Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

Biologically female
Age ≥ 18
Obesity as defined by current BMI ≥ 30 kg/m² or ≥ 27.5 kg/m² for individuals of Asian ancestry
Postmenopausal as defined by one or more of the following
* Age ≥60 years
* Age \<60 years with amenorrhea for ≥ 1 year
* Documented bilateral surgical oophorectomy
* Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial
HR+ (ER and/or PR) stage 0-III breast cancer
Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment
Insurance approval for tirzepatide or willing to pay out of pocket
Willing to provide informed consent and comply with study procedures

Stage IV breast cancer
Concomitant use of CDK inhibitors
Concomitant use of antiHER2 therapy
The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications
Other active malignancy requiring treatment
Enrollment in another investigational clinical trial
Contraindication to tirzepatide
Treatment with a GLP-1 receptor agonist within the last 3 months
Diabetes requiring insulin

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors